FDA-approved1,2Evidence: Large human trialsHormones · Bone and growth

Etelcalcetide1

Also called Parsabiv1,2

Key takeaway

Etelcalcetide is a synthetic peptide that activates the calcium-sensing receptor on the parathyroid glands, and the active ingredient in Parsabiv.1,2 FDA approved Parsabiv in 2017 for secondary hyperparathyroidism, overactive parathyroid glands caused by kidney failure, in adults on hemodialysis.1,2 In two randomized, placebo-controlled trials of more than 1,000 adults, about three in four on etelcalcetide cut parathyroid hormone by more than 30%, versus about one in ten on placebo. The label warns of low blood calcium.1

Etelcalcetide at a glance

What it isA synthetic peptide calcimimetic: it binds the calcium-sensing receptor and makes it more responsive to calcium, which lowers parathyroid hormone release, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Parsabiv with an original approval date of February 7, 2017. The cited label has no boxed warning.1,2
Human evidenceTwo 26-week randomized, double-blind, placebo-controlled trials in 508 and 515 adults on hemodialysis, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is etelcalcetide?

Etelcalcetide is a synthetic peptide agonist of the calcium-sensing receptor, according to the label.1

In the United States it is the active ingredient of Parsabiv, approved under NDA 208325, according to Drugs@FDA.2

How does etelcalcetide work?

The label states that etelcalcetide binds the calcium-sensing receptor and enhances its activation by calcium in the blood. Activating this receptor on parathyroid cells lowers the release of parathyroid hormone (PTH).1

What do human studies show?

The label describes two 26-week randomized, double-blind, placebo-controlled trials in adults with secondary hyperparathyroidism on hemodialysis: Study 1 in 508 patients and Study 2 in 515.1

The main outcome was a more than 30% fall in PTH. It was reached by 77% on etelcalcetide versus 11% on placebo in Study 1, and 79% versus 11% in Study 2, according to the label.1

Blood calcium and phosphate also fell more with etelcalcetide than with placebo, according to the label.1

What the evidence base contains

  • Large randomized human trial Study 1: a 26-week randomized, double-blind, placebo-controlled trial in 508 adults with secondary hyperparathyroidism on hemodialysis, described in the label.1
  • Large randomized human trial Study 2: a 26-week randomized, double-blind, placebo-controlled trial in 515 adults with secondary hyperparathyroidism on hemodialysis, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is etelcalcetide FDA-approved?

Yes. Drugs@FDA lists Parsabiv, application NDA 208325, with an original approval date of February 7, 2017.2

The Parsabiv label cited here (DailyMed SPL version 15, published March 16, 2026) states that it is indicated for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, and that it has not been studied in people with kidney disease who are not on hemodialysis.1

The label has no boxed warning. Its warnings include low blood calcium, which can be severe, worsening heart failure, upper gastrointestinal bleeding, and adynamic bone disease if PTH is suppressed too long.1

Timeline

  1. FDA approves Parsabiv, according to Drugs@FDA.2
  2. DailyMed publishes the Parsabiv label version cited on this page.1

What is still unknown?

Whether lowering PTH with it reduces fractures, heart problems or deaths: the label’s trials measured PTH, calcium and phosphate over 26 weeks.1

Its use in parathyroid cancer, primary hyperparathyroidism or kidney disease without hemodialysis, which the label states were not studied.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Etelcalcetide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Etelcalcetide are a bounded selection, not every registration or paper about Etelcalcetide. For the years before Etelcalcetide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Etelcalcetide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Etelcalcetide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Parsabiv for secondary hyperparathyroidism on hemodialysis. Two randomized, placebo-controlled trials of 508 and 515 adults described in the label found larger falls in parathyroid hormone with etelcalcetide. The label warns of low blood calcium.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Etelcalcetide?

FDA-approved as Parsabiv for secondary hyperparathyroidism on hemodialysis. Two randomized, placebo-controlled trials of 508 and 515 adults described in the label found larger falls in parathyroid hormone with etelcalcetide. The label warns of low blood calcium.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
9
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.↗Source date October 31, 2026
  2. Literature metadata · added November 15, 2026

    Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.↗Source date October 12, 2026
  3. Literature metadata · added November 15, 2026

    Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.↗Source date October 12, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Etelcalcetide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

47Selected dated records
49Connected citations
9Populated source years2017–2026
3/4Record lanes present

Registered human studies

Trial composition

17 of 17 selected trial records include at least one phase value; 17 of 17 include a status value in the retained structured contract.

PhasesPhase 3 9Phase 1 4Phase 2 4
Status at observationCompleted 15Recruiting 2

PubMed bibliography

Publication composition

28 of 28 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 26Review 7Research Support, Non-U.S. Gov't 4Case Reports 3Observational Study 3Multicenter Study 2Practice Guideline 2Clinical Trial, Phase IV 1Comparative Study 1Editorial 1Letter 1Meta-Analysis 1Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
47

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 47 dated records

Research hub

Explore the Etelcalcetide evidence record

Open all 47 records →
47Dated records
3Evidence types
47Cited public sources
9Source years

Change ledger

Recently changed for Etelcalcetide

Open all 47 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT01134549

PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide.

PeptideScanner change date
November 15, 2026
Cited source date
April 14, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01134562

PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.

PeptideScanner change date
November 15, 2026
Cited source date
January 2, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01254565

PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.

PeptideScanner change date
November 15, 2026
Cited source date
April 13, 2017
Evidence lane
Clinical trials

Official-source collections

Source records for Etelcalcetide

Open the full research atlas →
PubMed28

28 with attributed title, venue, publication-date, and type metadata.

  1. Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.CEN case reports · 2026 10 09
  2. Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up.Journal of clinical medicine · 2026 08 28
  3. Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.Clinical nephrology · 2025
Explore all selected literature →
ClinicalTrials.gov17

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03969329Registry update August 21, 2026 · current at observation
  2. NCT03633708Registry update February 27, 2026 · current at observation
  3. NCT03960437Registry update September 21, 2023 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span February 7, 2017 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 47

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.↗

    PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.↗

    PubMed lists PMID 29691773 in PharmacoEconomics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-11 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.↗

    PubMed lists PMID 42853437 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-09 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.↗

    PubMed lists PMID 28063122 in Journal of pharmacokinetics and pharmacodynamics as Journal Article, with publication-date metadata of 2017-01-06 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.↗

    PubMed lists PMID 41307414 in Clinical nephrology as Journal Article, Observational Study, Clinical Trial, Phase IV, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up.↗

    PubMed lists PMID 42739661 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-08-28 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina.↗

    PubMed lists PMID 39557587 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Journal Article, Observational Study, Multicenter Study, with publication-date metadata of 2024-11-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT03969329↗

    PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  9. Literature metadata

    Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation.↗

    PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT03633708↗

    PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide.↗

  11. Literature metadata

    Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis.↗

    PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.↗

    PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    PARSABIV (etelcalcetide) injection, solution · SPL version 15 · published 2026-03-16 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: PARSABIV (etelcalcetide), NDA 208325 · original approval February 7, 2017 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026